Discounted Cash Flow (DCF) Analysis Unlevered

Nymox Pharmaceutical Corporation (NYMX)

$0.1999

-0.00 (-0.05%)
All numbers are in Millions, Currency in USD
Stock DCF: -0.01 | 0.1999 | overvalue

Operating Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 0.300.120.010000000
Revenue (%)
EBITDA -10.57-12.55-11.43-12.24-6.29-0.41-0.09-0.02-0-0
EBITDA (%)
EBIT -10.57-13.11-11.69-12.50-6.54-0.42-0.09-0.02-0-0
EBIT (%)
Depreciation 00.570.270.250.250.010000
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash 7.955.243.610.831.400.080.02000
Total Cash (%)
Account Receivables 0.010.020.020.010.0100000
Account Receivables (%)
Inventories 0.040.020.030.030.0300000
Inventories (%)
Accounts Payable 0.811.631.401.271.700.090.02000
Accounts Payable (%)
Capital Expenditure -0.04-0.01-0-0-0-0-0-0-0-0
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.1,999
Beta 0.822
Diluted Shares Outstanding 89.38
Cost of Debt
Tax Rate 0.08
After-tax Cost of Debt 24.84%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.221
Total Debt 0.17
Total Equity 17.87
Total Capital 18.04
Debt Weighting 0.96
Equity Weighting 99.04
Wacc

Build Up Free Cash

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 0.300.120.010000000
EBITDA -10.57-12.55-11.43-12.24-6.29-0.41-0.09-0.02-0-0
EBIT -10.57-13.11-11.69-12.50-6.54-0.42-0.09-0.02-0-0
Tax Rate 0.00%-0.29%-0.36%-0.31%0.08%-0.18%-0.18%-0.18%-0.18%-0.18%
EBIAT -10.57-13.15-11.73-12.53-6.53-0.42-0.09-0.02-0-0
Depreciation 00.570.270.250.250.010000
Accounts Receivable --0-00.0100.010000
Inventories -0.02-0.01-00.010.030000
Accounts Payable -0.82-0.23-0.130.42-1.61-0.07-0.01-0-0
Capital Expenditure -0.04-0.01-0.01-0.01-0-0-0-0-0-0
UFCF -10.60-11.76-11.71-12.40-5.85-1.98-0.16-0.03-0.01-0
WACC
PV UFCF -13.44-5.85-1.83-0.13-0.03-0.01-0
SUM PV UFCF -1.99

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 8.38
Free cash flow (t + 1) -0
Terminal Value -0.02
Present Value of Terminal Value -0.02

Intrinsic Value

Enterprise Value -2.01
Net Debt -1.23
Equity Value -0.78
Shares Outstanding 89.38
Equity Value Per Share -0.01